{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:54Z","timestamp":1792787274724,"version":"4.5.0"},"reference-count":49,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"David Borsook Project"},{"name":"Brain Harvard Medical School, Massachusetts General Hospital","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/bmjopen-2026-122747","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:30:34Z","timestamp":1791552634000},"page":"e122747","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative health outcomes of buprenorphine versus methadone treatment for opioid use disorder: a retrospective propensity score-matched cohort study in the global federated electronic health record network"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-2677","authenticated-orcid":false,"given":"Igor","family":"Elman","sequence":"first","affiliation":[{"name":"Cambridge Health Alliance Mental Health and Addictions, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Albanese","sequence":"additional","affiliation":[{"name":"Cambridge Health Alliance, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Physician Health Services, Massachusetts Medical Society, Waltham, Massachusetts, USA"},{"name":"North Charles Institute for the Addictions Opioid Treatment Program, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisha","family":"Panchal","sequence":"additional","affiliation":[{"name":"Division of Ophthalmology, Department of Surgery, UMass Chan - Lahey School of Medicine, Burlington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J","family":"Elman","sequence":"additional","affiliation":[{"name":"Northeastern University, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-812X","authenticated-orcid":false,"given":"David J","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Division of Ophthalmology, Department of Surgery, UMass Chan - Lahey School of Medicine, Burlington, Massachusetts, USA"},{"name":"Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2026100906302230000_16.10.e122747.1","unstructured":"Centers for Disease Control and Prevention . National center for health statistics.provisional drug overdose death counts. 2025. Available: https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm [Accessed 24 Aug 2026]."},{"key":"2026100906302230000_16.10.e122747.2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jsat.2018.03.001","article-title":"Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review","volume":"89","author":"Maglione","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"2026100906302230000_16.10.e122747.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0094-5"},{"key":"2026100906302230000_16.10.e122747.4","doi-asserted-by":"crossref","first-page":"108055","DOI":"10.1016\/j.amepre.2025.108055","article-title":"Buprenorphine Dispensation After X-Waiver Elimination by Clinician Specialty","volume":"69","author":"Stone","year":"2025","journal-title":"Am J Prev Med"},{"key":"2026100906302230000_16.10.e122747.5","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00637-z"},{"key":"2026100906302230000_16.10.e122747.6","unstructured":"Coherent Market Insights Pvt Ltd . Buprenorphine market analysis & forcast: 2026-2033. 2026. Available: https:\/\/www.coherentmarketinsights.com\/market-insight\/buprenorphine-market-4237 [Accessed 17 Aug 2026]."},{"key":"2026100906302230000_16.10.e122747.7","article-title":"Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort study","volume":"28","author":"Williams","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2026100906302230000_16.10.e122747.8","unstructured":"Coherent Market Insights Pvt Ltd . Methadone hydrochloride market size and share analysis 2026 to 2033. 2026. Available: https:\/\/www.coherentmarketinsights.com\/market-insight\/methadone-hydrochloride-market-4343 [Accessed 17 Aug 2026]."},{"key":"2026100906302230000_16.10.e122747.9","first-page":"164","article-title":"The methadone fix","volume":"86","year":"2008","journal-title":"Bull World Health Organ"},{"key":"2026100906302230000_16.10.e122747.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32229-9"},{"key":"2026100906302230000_16.10.e122747.11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9140","article-title":"Current status of opioid addiction treatment and related preclinical research","volume":"5","author":"Kreek","year":"2019","journal-title":"Sci Adv"},{"key":"2026100906302230000_16.10.e122747.12","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jfda.2013.09.037","article-title":"Medication-assisted treatment for opioid addiction: Methadone and buprenorphine","volume":"21","author":"Saxon","year":"2013","journal-title":"J Food Drug Anal"},{"key":"2026100906302230000_16.10.e122747.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.04.015"},{"key":"2026100906302230000_16.10.e122747.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00088-4"},{"key":"2026100906302230000_16.10.e122747.15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.36076\/ppj.2009\/12\/679","article-title":"Opioid induced hyperalgesia: clinical implications for the pain practitioner","volume":"12","author":"Silverman","year":"2009","journal-title":"Pain Physician"},{"key":"2026100906302230000_16.10.e122747.16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26077","article-title":"Hospital-Based Methadone and Buprenorphine Initiation Practices by Addiction Consult Services","volume":"8","author":"Cohen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026100906302230000_16.10.e122747.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-62556-0","article-title":"Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone","volume":"10","author":"Elman","year":"2020","journal-title":"Sci Rep"},{"key":"2026100906302230000_16.10.e122747.18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301051"},{"key":"2026100906302230000_16.10.e122747.19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40429-023-00493-4","article-title":"Metabolic profiles associated with opioid use and opioid use disorder: a narrative review of the literature","volume":"10","author":"Byanyima","year":"2023","journal-title":"Curr Addict Rep"},{"key":"2026100906302230000_16.10.e122747.20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"2026100906302230000_16.10.e122747.21","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/Naloxone vs Methadone for the Treatment of Opioid Use Disorder","volume":"332","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"key":"2026100906302230000_16.10.e122747.22","unstructured":"TriNetX . Real-world data for the life sciences and healthcare. 2026. Available: https:\/\/trinetx.com\/ [Accessed 24 Aug 2026]."},{"key":"2026100906302230000_16.10.e122747.23","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)61602-x"},{"key":"2026100906302230000_16.10.e122747.24","doi-asserted-by":"crossref","unstructured":"Pan JY , Elman I , Panchal K , et al . GLP-1 Receptor Agonist Treatment and Health Outcomes in Methadone-Treated Patients with Opioid Use Disorder and Diabetes. J Gen Intern Med 2026. doi:10.1007\/s11606-026-10515-2","DOI":"10.1007\/s11606-026-10515-2"},{"key":"2026100906302230000_16.10.e122747.25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25889","article-title":"Evaluation of a Patient-Centered Fall-Prevention Tool Kit to Reduce Falls and Injuries: A Nonrandomized Controlled Trial","volume":"3","author":"Dykes","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026100906302230000_16.10.e122747.26","doi-asserted-by":"crossref","first-page":"100161","DOI":"10.1016\/j.ssmqr.2022.100161","article-title":"Variation in intervention stigma among medications for opioid use disorder","volume":"2","author":"Madden","year":"2022","journal-title":"SSM - Qualitative Research in Health"},{"key":"2026100906302230000_16.10.e122747.27","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.91934"},{"key":"2026100906302230000_16.10.e122747.28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of Racial\/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026100906302230000_16.10.e122747.29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.acvd.2022.11.007","article-title":"Prolongation of the heart rate-corrected QT interval is associated with cardiovascular diseases: Systematic review and meta-analysis","volume":"116","author":"Welten","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"key":"2026100906302230000_16.10.e122747.30","first-page":"577","article-title":"A systematic review of the cardiotoxicity of methadone","volume":"14","author":"Alinejad","year":"2015","journal-title":"EXCLI J"},{"key":"2026100906302230000_16.10.e122747.31","first-page":"5","article-title":"Opioid System Modulates the Immune Function: A Review","volume":"1","author":"Liang","year":"2016","journal-title":"Transl Perioper Pain Med"},{"key":"2026100906302230000_16.10.e122747.32","unstructured":"Tobin EH , Zahra F . Nosocomial Infections. StatPearls, 2025. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559312\/ [accessed 24 Aug 2026]."},{"key":"2026100906302230000_16.10.e122747.33","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8416763","article-title":"Oxidative Stress: Harms and Benefits for Human Health","volume":"2017","author":"Pizzino","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"2026100906302230000_16.10.e122747.34","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i3.456"},{"key":"2026100906302230000_16.10.e122747.35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/YCO.0000000000000992","article-title":"Treatments for weight gain in schizophrenia","volume":"38","author":"Elman","year":"2025","journal-title":"Curr Opin Psychiatry"},{"key":"2026100906302230000_16.10.e122747.36","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5478708","article-title":"Oxidative Stress in the Pathophysiology of Kidney Disease: Implications for Noninvasive Monitoring and Identification of Biomarkers","volume":"2020","author":"Gyur\u00e1szov\u00e1","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"2026100906302230000_16.10.e122747.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2009.00005.x"},{"key":"2026100906302230000_16.10.e122747.38","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/ael051"},{"key":"2026100906302230000_16.10.e122747.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2004.05.002"},{"key":"2026100906302230000_16.10.e122747.40","first-page":"462","article-title":"Keeping patients safe from methadone overdoses","volume":"36","author":"Grissinger","year":"2011","journal-title":"P T"},{"key":"2026100906302230000_16.10.e122747.41","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1111\/j.1526-4637.2011.01134.x","article-title":"An Analysis of the Root Causes for Opioid-Related Overdose Deaths in the United States","volume":"12","author":"Webster","year":"2011","journal-title":"Pain Med"},{"key":"2026100906302230000_16.10.e122747.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00195-0"},{"key":"2026100906302230000_16.10.e122747.43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12955-020-01599-3","article-title":"The effect of methadone on depression among addicts: a systematic review and meta-analysis","volume":"18","author":"Mohammadi","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2026100906302230000_16.10.e122747.44","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1038\/s41591-025-03800-w","article-title":"Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study","volume":"31","author":"Jelen","year":"2025","journal-title":"Nat Med"},{"key":"2026100906302230000_16.10.e122747.45","doi-asserted-by":"publisher","DOI":"10.1093\/ilar.52.3.342"},{"key":"2026100906302230000_16.10.e122747.46","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a039602","article-title":"Glutamatergic Systems and Memory Mechanisms Underlying Opioid Addiction","volume":"11","author":"Heinsbroek","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026100906302230000_16.10.e122747.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(99)00020-X"},{"key":"2026100906302230000_16.10.e122747.48","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2021.722323","article-title":"Glutamate: The Master Neurotransmitter and Its Implications in Chronic Stress and Mood Disorders","volume":"15","author":"Pal","year":"2021","journal-title":"Front Hum Neurosci"},{"key":"2026100906302230000_16.10.e122747.49","article-title":"Demographics and Clinical Characteristics of Patients With Opioid Use Disorder and Offered Medication-Assisted Treatment in the Emergency Department","volume":"15","author":"Fu","year":"2023","journal-title":"Cureus"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-122747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:30:39Z","timestamp":1791552639000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-122747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,9]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjopen-2026-122747"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-122747","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}